Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog. In draft guidance issued on Wednesday, the National Institute for Health and Care Excellence said using Opdivo, or nivolumab, in non-small cell lung cancer after chemotherapy did not represent a cost-effective use of resources.
Are you up for a challenge?
